Navigation Links
Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
Date:1/9/2012

ALBUQUERQUE, N.M., Jan. 9, 2012 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty focused molecular diagnostics laboratory that discovers, develops and markets proprietary tests for rheumatologists and gastroenterologists, announced today the launch of Avise SLE, which aids in the diagnosis of lupus (Systemic Lupus Erythematosus).

Avise SLE is a 5-marker panel designed to Rule-In SLE and Rule-Out other rheumatic diseases to help establish the most accurate SLE diagnosis. Specifically, the panel includes testing of ANA, dsDNA, Avise MCV, EC4d and BC4d. The Avise SLE diagnostic differentiates itself by using cell-bound complements because of their increased performance over soluble complements which helps to accurately and consistently diagnose SLE.

Avise SLE is most impactful when ordered as a first step in patient treatment to help physicians with diagnosis by providing:

  • Efficiency - 5 individual markers, 1 blood draw
  • Confidence in Diagnosis - From a panel that rules-in SLE and rules-out other rheumatic diseases
  • Increased Accuracy - Using CB-CAPs technology to achieve 78% sensitivity and 87% specificity for other diseases/97% specificity for normal/healthy patients
  • Convenience - We provide kits, pay shipping costs and return test results in 7 business days

 

"Exagen is excited to offer a breakthrough diagnostic that uses CB-CAPs technology to help accurately determine if a patient has lupus," said Ron Rocca, President and CEO. "Because diagnosing lupus is so difficult and early diagnosis is critical in avoiding major organ damage, developing an accurate diagnostic to fill the unmet need for rheumatologists was a top priority. We have been able to do that with Avise SLE and are pleased to take part in helping physicians gain control over this serious disease."

About Exagen

Exagen Diagnostics, Inc. is a patient focused, discovery driven, CLIA registered, CAP certified laboratory with a growing menu of proprietary, internally developed tests focused in the areas of Rheumatology and Gastroenterology. Committed to Personalized Medicine, our tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.  Using uniquely powerful Coperna® discovery technology, Exagen identifies and validates small sets of genomic markers which are used to create meaningful, easily interpreted diagnostic tests for clinical use. For more information, please visit www.Exagen.com or www.AviseTest.com.


'/>"/>
SOURCE Exagen Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Eric Tornoe Joins Exagen Diagnostics as President and COO
2. Exagen Diagnostics Awarded $400,000 in Grants Under the QTDP Program
3. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
4. S.E.D. Labs to be Acquired by Quest Diagnostics
5. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
6. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
7. Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
8. Quest Diagnostics Encourages Denver Area Residents to Enroll in Historic American Cancer Society Prevention Study November 8th - 19th
9. Quest Diagnostics Initiates CEO Succession Process
10. Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology
11. Ambry Genetics First to Offer Exome Sequencing Service for Clinical Diagnostics.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, ... security market and how smart safety and security products impact the competitive ... Parks Associates: Smart Home Devices: Main ... "The residential security market has experienced continued ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
(Date:10/9/2017)... ... 09, 2017 , ... At its national board meeting in North Carolina, ... University’s Departments of Physics and Astronomy, has been selected for membership in ARCS ... for the 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating ...
Breaking Biology Technology:
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):